|
|
 |
|
Viewing report
|
|
|
|
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, June 2011, Pages: 71
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global anxiety disorders market. The report identifies the key trends shaping and driving the global anxiety disorders market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anxiety disorders sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global anxiety disorders therapeutics market was valued at $3,698m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.3% over the next seven years, to reach $5,689 m by 2017. This steady growth is primarily attributed to only one product launch for generalized anxiety disorder, disease awareness and alternate treatment options other than pharmacotherapy. Lu AA21004, currently in Phase III is the most promising products in the late stage pipeline. Drugs in the pipeline have shown encouraging response rates in pretreated patients and have great potential in the anxiety disorders therapeutics market. The pipeline candidates are mainly concentrated in the Phase II of clinical development.
Scope
The report provides information on the key drivers and challenges of the Anxiety disorders market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) anxiety disorders market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as serotonin receptor binders, adrenergic receptor anatagonist, corticotrophin-releasing factor antagonist, glutamate receptor modulator, GABA agonist, GABA receptor modulators, monoamine uptake inhibitor, mGluR agonist and vasopressin receptor antagonist and others.
- Analysis of the current and future competition in the global TBI market. Key market players covered are Lundbeck, Cenerex BioPharma, Eli Lilly and others.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the anxiety disorders therapeutics market.
- Analysis of key recent licensing and partnership agreements in anxiety disorders market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global anxiety disorders market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global anxiety disorders market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global anxiety disorders market landscape? – Identify, understand and capitalize.
|
|
|
|
